How Is The Autologous Stem Cell And Non-Stem Cell Based Therapies Market Expected To Grow At 15% CAGR Over 2025–2029?
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
What Are The Future Growth Projections For The Autologous Stem Cell And Non-Stem Cell Based Therapies Market Size?
The market for autologous stem cell and non-stem cell based therapies has seen robust growth in the recent past. The market size, which was at $9.96 billion in 2024, is predicted to swell to $11.49 billion in 2025, marking a compound annual growth rate (CAGR) of 15.5%. Key contributors to this previous period’s growth include a heightened occurrence of cancer and diabetes, a surge in the geriatric population, escalating awareness about healthcare, expansion in research and development endeavours, augmentation in the number of clinical trials, and an increase in regulatory approvals.
In the coming years, the market size for autologous stem cell and non-stem cell based therapies is projected to experience swift expansion. It is anticipated to reach a value of $20.07 billion in 2029, with a compound annual growth rate (CAGR) of 15.0%. This projected growth can be traced back to a number of factors including the growing occurrence of specific diseases, an aging population, increasing cases of neurodegenerative diseases, and a surge in cancer cases. Additionally, the growing demand for skin transplants, increased consciousness regarding regenerative medicine, and strategic collaborations among industry key players are also aiding the market growth. Improvements in the reimbursement for approved therapies is another driving factor. Future trends hint at an incorporation of artificial intelligence and machine learning, the creation of off-the-shelf allogeneic stem cell products, expansion of reimbursement policies, use of innovative biomaterials, advancement in cell manufacturing technologies, adoption of autologous stem cell therapies, and the integration of gene editing technologies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15729&type=smp
What Are The Primary Factors Supporting The Autologous Stem Cell And Non-Stem Cell Based Therapies Market Expansion?
The anticipated rise in demand for personalized treatments is predicted to fuel expansion in the market for autologous stem cell and non-stem cell-based therapies. These personalized therapies are medical procedures specifically structured to optimize benefits and reduce adverse outcomes, taking into account each patient’s distinct genetics, lifestyle, and preferences. An increase in these personalized therapies is attributed to various causes such as innovations in genetics and technology that enable more accurate and efficient remedies with lesser side effects, growing patient needs for customized medical care, and potential healthcare cost benefits. Through the customization of therapies to an individual’s unique genetic and health features, personalized therapies elevate the application of autologous stem cell and non-stem cell-based therapies, consequently leading to superior outcomes and lesser complications. For instance, the Personalized Medicine Coalition, an American professional membership organization, reported that in 2022, the nod of approval granted to 12 new personalized medicines made up roughly 34% of all fresh approved therapies – a notable rise from preceding years. Therefore, the burgeoning demand for personalized therapies is steering the market growth for autologous stem cell and non-stem cell-based therapies.
Which Segmentation Categories Are Highlighted In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market Analysis?
The autologous stem cell and non-stem cell based therapies market covered in this report is segmented –
1) By Type: Autologous Stem Cells, Autologous Non-Stem Cells, Other Types
2) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, Other Applications
3) By End-User: Hospitals, Ambulatory Surgical Centers, Research Facilities, Other End Users
Subsegments:
1) By Autologous Stem Cells: Hematopoietic Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Endothelial Stem Cells
2) By Autologous Non-Stem Cells: Platelet-Rich Plasma (Prp), Adipose-Derived Cells, Peripheral Blood Cells
3) By Other Types: Exosome-Based Therapies, Tissue-Engineered Constructs
Which Market Trends Are Expected To Define The Future Of The Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
The autologous stem cell and non-stem cell-based therapies market is witnessing advancements by prominent companies which are exploiting tumor-derived autologous T cell immunotherapy for augmenting personalized cancer care tactics. This therapy operates by extracting T cells from a patient’s tumor, proliferating and activating them in a laboratory, then reintroducing them to the patient to bolster the immune response specifically against cancer cells. As an example, in February 2024, the US-located biotechnology firm Iovance Biotherapeutics obtained expedited approval from the US federal agency, Food and Drug Administration, for Amtagvi (lifileucel), the inaugural cellular therapy designated for treating adult patients suffering from melanoma. Lifileucel is a tumor-derived autologous T-cell immunotherapy consisting of tumor-infiltrating lymphocytes (TILs) naturally present in the patient’s immune system. This assists in a more effective recognition and attack of the cancer by the patient’s immune system.
Which Companies Hold A Competitive Edge In The 395 Market?
Major companies operating in the autologous stem cell and non-stem cell based therapies market are Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck & Co. Inc., Stemcell Technologies Inc., Dendreon Corporation, Vericel Corporation, Sangamo Therapeutics Inc., NEOSTEM, Orgenesis Inc., Adaptimmune Therapeutics, Stempeutics Research Pvt Ltd., MEDIPOST, Castle Creek Biosciences Inc., BrainStorm Cell Limited, Athersys Inc., Cytori Therapeutics Inc., Opexa Therapeutics, Gamida Cell, Regen BioPharma Inc., RepliCel Life Sciences, InGeneron Inc., BioCardia Inc., ReNeuron Group
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market?
North America was the largest region in the autologous stem cell and non-stem cell based therapies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=15729&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
